Intrexon | XON - Debt


Intrexon reported $0 in Debt for its fiscal quarter ending in June of 2024.





Debt Change Date
Agenus USD 35.54M 2.34M Mar/2025
Alaunos Therapeutics USD 10.99M 5.78M Mar/2023
Amgen USD 57.32B 2.72B Mar/2026
Anika Therapeutics USD 0 0 Mar/2025
Arrowhead Research USD 983.69M 5.77M Jun/2026
AstraZeneca USD 32.24B 1.68B Jun/2026
Bristol-Myers Squibb USD 46.43B 711M Mar/2026
Gilead Sciences USD 22.17B 2.76B Mar/2026
GlaxoSmithKline GBP 19.06B 1.34B Mar/2026
Heron Therapeutics USD 149.65M 157K Sep/2024
Incyte USD 38.27M 1.16M Jun/2026
Intrexon USD 0 13.82M Jun/2024
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
Ligand Pharmaceuticals USD 451.98M 486K Mar/2026
MacroGenics USD 36.51M 500K Mar/2026
MannKind USD 330.96M 36.48M Mar/2026
Merck USD 49.12B 222M Mar/2026
Novartis USD 49.01B 2.02B Jun/2026
Rigel Pharmaceuticals USD 59.69M 90K Jun/2024
Roche Holding CHF 33.03B 1.41B Jun/2025
Sangamo BioSciences USD 0 0 Jun/2022
Thermo Fisher Scientific USD 43.16B 3.78B Mar/2026
Veracyte USD 39.33M 321K Mar/2026
Xencor USD 175.16M 12.58M Mar/2026